Get Live Data

focusIR May 2024 Investor Webinar: Blue Whale, Kavango, Taseko Mines & CQS Natural Resources. Catch up with the webinar here.

Less Ads, More Data, More Tools Register for FREE
Stephen Yiu, FM at WS Blue Whale, discusses Nvidia, Visa/Mastercard, Lam Research & Allied Materials
Stephen Yiu, FM at WS Blue Whale, discusses Nvidia, Visa/Mastercard, Lam Research & Allied MaterialsView Video
Ben Turney, CEO at Kavango Resources, explains the company's progress from exploration to mining
Ben Turney, CEO at Kavango Resources, explains the company's progress from exploration to miningView Video

Latest Share Chat

  2. Share Prices
  3. Faron Pharma Share Price
  4. Faron Pharma Share News
  5. Faron appoints Sensei Biotherapeutics's Marie-Louise Fjallskog as CMO

Pin to quick picksFaron Pharma Share News (FARN)

Faron Pharma Information

Share Price Information for Faron Pharma (FARN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 250.00
Bid: 240.00
Ask: 260.00
Change: 10.00 (4.17%)
Spread: 20.00 (8.333%)
Open: 238.00
High: 257.00
Low: 238.00
Prev. Close: 240.00
FARN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Faron appoints Sensei Biotherapeutics's Marie-Louise Fjallskog as CMO

Tue, 04th Jan 2022 15:54

(Alliance News) - Faron Pharmaceuticals Oy announced the appointment of Marie-Louise Fjallskog as new chief medical officer on Tuesday.

Fjallskog will join the Finland-based clinical-stage biopharmaceutical company, bringing 30 years of experience in clinical oncology, translational research and drug development.

She was previously chief medical officer at Nasdaq-listed Sensei Biotherapeutics Inc, where she played a key role in the company's USD150 million IPO in the first quarter of 2021.

Faron's chief executive officer, Markku Jalkanen, said: "I am delighted to welcome Marie-Louise to Faron as our Chief Medical Officer during what is a critical time for the Company as we accelerate the execution of our ambitious clinical development programs, including our lead oncology asset bexmarilimab."

The pharmaceutical company's share price rose by 8.4% to 290.00 pence on Tuesday afternoon in London.

By Elizabeth Winter; elizabethwinter@alliancenews.com

Copyright 2022 Alliance News Limited. All Rights Reserved.

More News
13 Feb 2019 12:20

Faron Pharmaceuticals Encouraged By Clever-1 Antibody Study Result

LONDON (Alliance News) - Faron Pharmaceuticals Ltd on Wednesday said new data supports the use of Clever-1 antibodies in re-activating an immune response to tumours.Shares in Faron were up

Read more
19 Dec 2018 11:07

Faron Pharmaceuticals pins some hope to YODA trial

(Sharecast News) - Clinical stage biopharmaceutical company Faron Pharmaceuticals issued interim results from its pharmacokinetic/dynamic 'YODA' study on Wednesday, examining various formulations of recombinant human interferon-beta (IFN-beta).

Read more
14 Dec 2018 15:57

Dosing begins in Faron's study of 'Clevegen' drug

(Sharecast News) - Clinical stage biopharmaceutical company Faron Pharmaceuticals announced on Friday that the first patient has successfully been dosed in the phase I/II MATINS study of Clevegen, its wholly-owned novel precision cancer immunotherapy drug.

Read more
5 Dec 2018 11:19

WINNERS & LOSERS SUMMARY: Ashtead Falls On US Economic Slowdown Worry

LONDON (Alliance News) - The following stocks are the leading risers and fallers within the main London indices on Wednesday.----------FTSE 100 - up 2.7%. Japan's Takeda Pharmaceutical

Read more
5 Dec 2018 10:13

Traumakine treatment optimal for particular subgroup, Faron finds

(Sharecast News) - Clinical stage biopharmaceutical company Faron Pharmaceuticals has identified, by genetic testing, an "optimal subgroup" of acute respiratory distress syndrome (ARDS) patients for Traumakine treatment who showed a substantial reduction in mortality during the INTEREST trial, it announced on Wednesday.

Read more
5 Dec 2018 09:09

Faron Pharmaceuticals Finds "Optimal" Patient Group For Traumakine

LONDON (Alliance News) - Faron Pharmaceuticals Ltd shares jumped on Wednesday as the company said it identified an "optimal" subgroup of patients, with a certain genetic mutation, to be

Read more
3 Dec 2018 10:50

WINNERS & LOSERS SUMMARY: McColl's Retail Plunges After Profit Warning

LONDON (Alliance News) - The following stocks are the leading risers and fallers within the main London indices on Monday.----------FTSE 100 - up 8.9%, Evraz, up 7.8%, up

Read more
3 Dec 2018 10:09

Faron Pharmaceuticals applies to begin Clevegen clinical trials

(Sharecast News) - Clinical stage biopharmaceutical company Faron Pharmaceuticals announced on Monday that its clinical trial application to conduct a Phase I/II study with 'Clevegen', its wholly-owned novel precision cancer immunotherapy drug in development for the treatment of selected metastatic or inoperable tumours, has been approved by the Finnish Medicines Agency (FIMEA).

Read more
6 Nov 2018 16:29

DIRECTOR DEALINGS: Faron Divisional Chief Medical Officer Buys Shares

LONDON (Alliance News) - Faron Pharmaceuticals Oy on Tuesday said VP Drug Development Chief Medical Officer Matti Karvonen acquired shares in the biopharmaceutical company.In a transaction

Read more
22 Oct 2018 15:32

Faron Reports Corticosteroids Interference In Traumakine Trial

LONDON (Alliance News) - Faron Pharmaceuticals Ltd said Monday that it has found evidence suggesting that corticosteroids used in parallel to its Traumakine treatment had a significant effect on a

Read more
17 Sep 2018 10:37

Faron Pharmaceuticals Submits Clinical Trial Application For Clevegen

LONDON (Alliance News) - Faron Pharmaceuticals Oy said Monday it has filed a clinical trial application for its cancer immunotherapy drug Clevegen.Clevegen, an anti-Clever-1 antibody, the a

Read more
13 Sep 2018 10:49

WINNERS & LOSERS SUMMARY: Retailers Hit As John Lewis Profit Collapses

LONDON (Alliance News) - The following stocks are the leading risers and fallers within the main London indices on Thursday.----------FTSE 100 - WINNERS----------Royal Bank a

Read more
13 Sep 2018 10:30

Faron Pharmaceuticals Falls As Interim Loss Widens On Research Costs

LONDON (Alliance News) - Shares in Faron Pharmaceuticals Ltd dropped on Thursday after the company said its loss for the first half of its financial year increased on higher research were trading

Read more
13 Sep 2018 08:36

Faron losses widen following disappointing Traumakine trial

(Sharecast News) - Faron Pharmaceuticals' operating loss doubled in the first half of its trading year following the group's disappointing trial on its Traumakine treatment.

Read more
12 Sep 2018 13:48

Faron Pharmaceuticals Says New Clever-1 Data Shows B Cell Response

LONDON (Alliance News) - Faron Pharmaceuticals Ltd said Wednesday that new data from its cell surface receptor Clever-1 showed B cell response control and humoral antibody production.The by

Read more
6789101112131415

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.